Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205379 | 0.93 | MEN1 (0.44) | NOS2MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL5204696 | 0.90 | CYP1A2 (0.46) | NOS2MEN1KMT2ASMN1; SMN2NOS1 | |
| SCHEMBL5201968 | 0.89 | NOS2 (0.53) | NOS2TSHR | |
| SCHEMBL5204903 | 0.87 | NOS2 (0.58) | NOS2 | |
| SCHEMBL5206004 | 0.85 | NOS2 (0.50) | NOS2TSHRNOS1 | |
| SCHEMBL5202231 | 0.83 | NOS2 (0.52) | NOS2HPGDALDH1A1TSHRNOS1 | |
| SCHEMBL5202697 | 0.78 | NOS2 (0.58) | NOS2NOS1 | |
| SCHEMBL5190897 | 0.70 | NOS2 (0.61) | NOS2NOS1 | |
| SCHEMBL7067249 | 0.69 | NOS2 (0.57) | NOS2ALDH1A1NOS1 | |
| SCHEMBL5190548 | 0.69 | NOS2 (0.63) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | claimed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | claimed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1795192-A2 | 1-Substituted imidazole derivatives as nos inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | disclosed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885MEN1 1105/4885KMT2A 2581/4885 |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885MEN1 1636/4885KMT2A 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.